nodes	percent_of_prediction	percent_of_DWPC	metapath
Propylthiouracil—DBH—nerve—acquired immunodeficiency syndrome	0.0312	0.131	CbGeAlD
Propylthiouracil—MPO—saliva—acquired immunodeficiency syndrome	0.029	0.122	CbGeAlD
Propylthiouracil—DIO1—lung—acquired immunodeficiency syndrome	0.0258	0.108	CbGeAlD
Propylthiouracil—MPO—endothelium—acquired immunodeficiency syndrome	0.0142	0.0598	CbGeAlD
Propylthiouracil—TPO—lymphoid tissue—acquired immunodeficiency syndrome	0.0141	0.0593	CbGeAlD
Propylthiouracil—TPO—digestive system—acquired immunodeficiency syndrome	0.0139	0.0585	CbGeAlD
Propylthiouracil—MPO—blood plasma—acquired immunodeficiency syndrome	0.0126	0.0531	CbGeAlD
Propylthiouracil—DBH—digestive system—acquired immunodeficiency syndrome	0.00907	0.0382	CbGeAlD
Propylthiouracil—DIO1—Amino acid and derivative metabolism—TAT—acquired immunodeficiency syndrome	0.00887	0.116	CbGpPWpGaD
Propylthiouracil—DBH—blood—acquired immunodeficiency syndrome	0.00864	0.0364	CbGeAlD
Propylthiouracil—DBH—bone marrow—acquired immunodeficiency syndrome	0.00836	0.0352	CbGeAlD
Propylthiouracil—DBH—nervous system—acquired immunodeficiency syndrome	0.00701	0.0295	CbGeAlD
Propylthiouracil—DBH—central nervous system—acquired immunodeficiency syndrome	0.00675	0.0284	CbGeAlD
Propylthiouracil—TPO—Hematopoietic Stem Cell Differentiation—CXCR4—acquired immunodeficiency syndrome	0.00627	0.082	CbGpPWpGaD
Propylthiouracil—MPO—skin of body—acquired immunodeficiency syndrome	0.00606	0.0255	CbGeAlD
Propylthiouracil—DBH—Amino acid and derivative metabolism—TAT—acquired immunodeficiency syndrome	0.00542	0.0708	CbGpPWpGaD
Propylthiouracil—DBH—brain—acquired immunodeficiency syndrome	0.00536	0.0226	CbGeAlD
Propylthiouracil—DBH—lymph node—acquired immunodeficiency syndrome	0.00518	0.0218	CbGeAlD
Propylthiouracil—TPO—Amino acid and derivative metabolism—TAT—acquired immunodeficiency syndrome	0.00509	0.0666	CbGpPWpGaD
Propylthiouracil—MPO—lymphoid tissue—acquired immunodeficiency syndrome	0.00491	0.0207	CbGeAlD
Propylthiouracil—MPO—digestive system—acquired immunodeficiency syndrome	0.00485	0.0204	CbGeAlD
Propylthiouracil—TPO—Hematopoietic Stem Cell Differentiation—CSF2—acquired immunodeficiency syndrome	0.0047	0.0614	CbGpPWpGaD
Propylthiouracil—MPO—blood—acquired immunodeficiency syndrome	0.00462	0.0195	CbGeAlD
Propylthiouracil—MPO—bone marrow—acquired immunodeficiency syndrome	0.00447	0.0188	CbGeAlD
Propylthiouracil—MPO—spinal cord—acquired immunodeficiency syndrome	0.00445	0.0187	CbGeAlD
Propylthiouracil—MPO—lung—acquired immunodeficiency syndrome	0.00405	0.0171	CbGeAlD
Propylthiouracil—MPO—nervous system—acquired immunodeficiency syndrome	0.00375	0.0158	CbGeAlD
Propylthiouracil—MPO—central nervous system—acquired immunodeficiency syndrome	0.00361	0.0152	CbGeAlD
Propylthiouracil—MPO—brain—acquired immunodeficiency syndrome	0.00287	0.0121	CbGeAlD
Propylthiouracil—DIO1—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	0.00284	0.0371	CbGpPWpGaD
Propylthiouracil—MPO—lymph node—acquired immunodeficiency syndrome	0.00277	0.0117	CbGeAlD
Propylthiouracil—DIO1—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	0.00259	0.0339	CbGpPWpGaD
Propylthiouracil—MPO—Vitamin B12 Metabolism—CCL5—acquired immunodeficiency syndrome	0.00246	0.0322	CbGpPWpGaD
Propylthiouracil—DBH—Monoamine Transport—TNF—acquired immunodeficiency syndrome	0.0023	0.0301	CbGpPWpGaD
Propylthiouracil—Leukopenia—Didanosine—acquired immunodeficiency syndrome	0.0021	0.00306	CcSEcCtD
Propylthiouracil—Neuropathy peripheral—Indinavir—acquired immunodeficiency syndrome	0.00206	0.003	CcSEcCtD
Propylthiouracil—Jaundice—Indinavir—acquired immunodeficiency syndrome	0.00205	0.00299	CcSEcCtD
Propylthiouracil—Alopecia—Abacavir—acquired immunodeficiency syndrome	0.00203	0.00296	CcSEcCtD
Propylthiouracil—Hepatitis—Zidovudine—acquired immunodeficiency syndrome	0.00203	0.00296	CcSEcCtD
Propylthiouracil—Arthralgia—Didanosine—acquired immunodeficiency syndrome	0.00199	0.00291	CcSEcCtD
Propylthiouracil—Myalgia—Didanosine—acquired immunodeficiency syndrome	0.00199	0.00291	CcSEcCtD
Propylthiouracil—Dysgeusia—Stavudine—acquired immunodeficiency syndrome	0.00199	0.0029	CcSEcCtD
Propylthiouracil—Drowsiness—Efavirenz—acquired immunodeficiency syndrome	0.00199	0.0029	CcSEcCtD
Propylthiouracil—Neuropathy peripheral—Efavirenz—acquired immunodeficiency syndrome	0.00195	0.00284	CcSEcCtD
Propylthiouracil—MPO—Folate Metabolism—IL4—acquired immunodeficiency syndrome	0.00194	0.0254	CbGpPWpGaD
Propylthiouracil—Jaundice—Efavirenz—acquired immunodeficiency syndrome	0.00194	0.00282	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Amprenavir—acquired immunodeficiency syndrome	0.00191	0.00278	CcSEcCtD
Propylthiouracil—Haemoglobin—Indinavir—acquired immunodeficiency syndrome	0.0019	0.00277	CcSEcCtD
Propylthiouracil—Hepatitis—Indinavir—acquired immunodeficiency syndrome	0.00189	0.00275	CcSEcCtD
Propylthiouracil—Haemorrhage—Indinavir—acquired immunodeficiency syndrome	0.00189	0.00275	CcSEcCtD
Propylthiouracil—Paraesthesia—Amprenavir—acquired immunodeficiency syndrome	0.00188	0.00274	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Didanosine—acquired immunodeficiency syndrome	0.00187	0.00273	CcSEcCtD
Propylthiouracil—MPO—IL23-mediated signaling events—IFNG—acquired immunodeficiency syndrome	0.00187	0.0244	CbGpPWpGaD
Propylthiouracil—Neuropathy peripheral—Delavirdine—acquired immunodeficiency syndrome	0.00186	0.00272	CcSEcCtD
Propylthiouracil—Jaundice—Delavirdine—acquired immunodeficiency syndrome	0.00185	0.0027	CcSEcCtD
Propylthiouracil—Leukopenia—Nelfinavir—acquired immunodeficiency syndrome	0.00183	0.00266	CcSEcCtD
Propylthiouracil—Leukopenia—Stavudine—acquired immunodeficiency syndrome	0.00182	0.00265	CcSEcCtD
Propylthiouracil—MPO—IL23-mediated signaling events—CD4—acquired immunodeficiency syndrome	0.0018	0.0235	CbGpPWpGaD
Propylthiouracil—Vertigo—Abacavir—acquired immunodeficiency syndrome	0.0018	0.00262	CcSEcCtD
Propylthiouracil—Leukopenia—Abacavir—acquired immunodeficiency syndrome	0.00179	0.00261	CcSEcCtD
Propylthiouracil—Arthralgia—Nevirapine—acquired immunodeficiency syndrome	0.00179	0.00261	CcSEcCtD
Propylthiouracil—Myalgia—Nevirapine—acquired immunodeficiency syndrome	0.00179	0.00261	CcSEcCtD
Propylthiouracil—Hepatitis—Efavirenz—acquired immunodeficiency syndrome	0.00178	0.0026	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Didanosine—acquired immunodeficiency syndrome	0.00174	0.00254	CcSEcCtD
Propylthiouracil—Arthralgia—Nelfinavir—acquired immunodeficiency syndrome	0.00174	0.00253	CcSEcCtD
Propylthiouracil—Myalgia—Nelfinavir—acquired immunodeficiency syndrome	0.00174	0.00253	CcSEcCtD
Propylthiouracil—Arthralgia—Stavudine—acquired immunodeficiency syndrome	0.00173	0.00252	CcSEcCtD
Propylthiouracil—Myalgia—Stavudine—acquired immunodeficiency syndrome	0.00173	0.00252	CcSEcCtD
Propylthiouracil—Dysgeusia—Zidovudine—acquired immunodeficiency syndrome	0.00173	0.00252	CcSEcCtD
Propylthiouracil—Neuropathy peripheral—Ritonavir—acquired immunodeficiency syndrome	0.00172	0.00251	CcSEcCtD
Propylthiouracil—Oedema—Nevirapine—acquired immunodeficiency syndrome	0.00172	0.00251	CcSEcCtD
Propylthiouracil—Paraesthesia—Didanosine—acquired immunodeficiency syndrome	0.00172	0.0025	CcSEcCtD
Propylthiouracil—Jaundice—Ritonavir—acquired immunodeficiency syndrome	0.00171	0.0025	CcSEcCtD
Propylthiouracil—Hepatitis—Delavirdine—acquired immunodeficiency syndrome	0.00171	0.00249	CcSEcCtD
Propylthiouracil—Myalgia—Abacavir—acquired immunodeficiency syndrome	0.00171	0.00249	CcSEcCtD
Propylthiouracil—Arthralgia—Abacavir—acquired immunodeficiency syndrome	0.00171	0.00249	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Nevirapine—acquired immunodeficiency syndrome	0.00168	0.00245	CcSEcCtD
Propylthiouracil—Dyspepsia—Didanosine—acquired immunodeficiency syndrome	0.00168	0.00245	CcSEcCtD
Propylthiouracil—DIO1—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	0.00168	0.0219	CbGpPWpGaD
Propylthiouracil—Alopecia—Indinavir—acquired immunodeficiency syndrome	0.00167	0.00243	CcSEcCtD
Propylthiouracil—Oedema—Nelfinavir—acquired immunodeficiency syndrome	0.00166	0.00243	CcSEcCtD
Propylthiouracil—Neuropathy peripheral—Saquinavir—acquired immunodeficiency syndrome	0.00166	0.00242	CcSEcCtD
Propylthiouracil—MPO—IL23-mediated signaling events—IL2—acquired immunodeficiency syndrome	0.00166	0.0217	CbGpPWpGaD
Propylthiouracil—Jaundice—Saquinavir—acquired immunodeficiency syndrome	0.00165	0.0024	CcSEcCtD
Propylthiouracil—Oedema—Abacavir—acquired immunodeficiency syndrome	0.00163	0.00238	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Nelfinavir—acquired immunodeficiency syndrome	0.00163	0.00238	CcSEcCtD
Propylthiouracil—DIO1—Metabolism—TAT—acquired immunodeficiency syndrome	0.00163	0.0213	CbGpPWpGaD
Propylthiouracil—Thrombocytopenia—Stavudine—acquired immunodeficiency syndrome	0.00162	0.00237	CcSEcCtD
Propylthiouracil—Dysgeusia—Indinavir—acquired immunodeficiency syndrome	0.00161	0.00235	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Abacavir—acquired immunodeficiency syndrome	0.0016	0.00233	CcSEcCtD
Propylthiouracil—Vertigo—Zidovudine—acquired immunodeficiency syndrome	0.00159	0.00231	CcSEcCtD
Propylthiouracil—Haemoglobin—Ritonavir—acquired immunodeficiency syndrome	0.00159	0.00231	CcSEcCtD
Propylthiouracil—Neuropathy peripheral—Lamivudine—acquired immunodeficiency syndrome	0.00158	0.00231	CcSEcCtD
Propylthiouracil—Leukopenia—Zidovudine—acquired immunodeficiency syndrome	0.00158	0.00231	CcSEcCtD
Propylthiouracil—MPO—Vitamin B12 Metabolism—ALB—acquired immunodeficiency syndrome	0.00158	0.0207	CbGpPWpGaD
Propylthiouracil—Hepatitis—Ritonavir—acquired immunodeficiency syndrome	0.00158	0.0023	CcSEcCtD
Propylthiouracil—Haemorrhage—Ritonavir—acquired immunodeficiency syndrome	0.00158	0.0023	CcSEcCtD
Propylthiouracil—Alopecia—Efavirenz—acquired immunodeficiency syndrome	0.00158	0.0023	CcSEcCtD
Propylthiouracil—Jaundice—Lamivudine—acquired immunodeficiency syndrome	0.00157	0.00229	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Nevirapine—acquired immunodeficiency syndrome	0.00157	0.00228	CcSEcCtD
Propylthiouracil—Paraesthesia—Nevirapine—acquired immunodeficiency syndrome	0.00154	0.00225	CcSEcCtD
Propylthiouracil—Somnolence—Nevirapine—acquired immunodeficiency syndrome	0.00153	0.00223	CcSEcCtD
Propylthiouracil—Haemoglobin—Saquinavir—acquired immunodeficiency syndrome	0.00153	0.00223	CcSEcCtD
Propylthiouracil—Dysgeusia—Efavirenz—acquired immunodeficiency syndrome	0.00152	0.00222	CcSEcCtD
Propylthiouracil—Haemorrhage—Saquinavir—acquired immunodeficiency syndrome	0.00152	0.00221	CcSEcCtD
Propylthiouracil—Hepatitis—Saquinavir—acquired immunodeficiency syndrome	0.00152	0.00221	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Nelfinavir—acquired immunodeficiency syndrome	0.00152	0.00221	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Stavudine—acquired immunodeficiency syndrome	0.00151	0.0022	CcSEcCtD
Propylthiouracil—Body temperature increased—Didanosine—acquired immunodeficiency syndrome	0.00151	0.0022	CcSEcCtD
Propylthiouracil—Alopecia—Delavirdine—acquired immunodeficiency syndrome	0.00151	0.0022	CcSEcCtD
Propylthiouracil—Agranulocytosis—Lamivudine—acquired immunodeficiency syndrome	0.00151	0.0022	CcSEcCtD
Propylthiouracil—Myalgia—Zidovudine—acquired immunodeficiency syndrome	0.0015	0.00219	CcSEcCtD
Propylthiouracil—Arthralgia—Zidovudine—acquired immunodeficiency syndrome	0.0015	0.00219	CcSEcCtD
Propylthiouracil—Paraesthesia—Nelfinavir—acquired immunodeficiency syndrome	0.00149	0.00218	CcSEcCtD
Propylthiouracil—Paraesthesia—Stavudine—acquired immunodeficiency syndrome	0.00149	0.00217	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Abacavir—acquired immunodeficiency syndrome	0.00149	0.00217	CcSEcCtD
Propylthiouracil—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.00148	0.00216	CcSEcCtD
Propylthiouracil—Somnolence—Nelfinavir—acquired immunodeficiency syndrome	0.00148	0.00216	CcSEcCtD
Propylthiouracil—Vertigo—Indinavir—acquired immunodeficiency syndrome	0.00148	0.00215	CcSEcCtD
Propylthiouracil—Somnolence—Stavudine—acquired immunodeficiency syndrome	0.00148	0.00215	CcSEcCtD
Propylthiouracil—Paraesthesia—Abacavir—acquired immunodeficiency syndrome	0.00147	0.00214	CcSEcCtD
Propylthiouracil—Dyspepsia—Nelfinavir—acquired immunodeficiency syndrome	0.00147	0.00214	CcSEcCtD
Propylthiouracil—Dyspepsia—Stavudine—acquired immunodeficiency syndrome	0.00146	0.00213	CcSEcCtD
Propylthiouracil—TPO—Hematopoietic Stem Cell Differentiation—IL6—acquired immunodeficiency syndrome	0.00146	0.0191	CbGpPWpGaD
Propylthiouracil—Dysgeusia—Delavirdine—acquired immunodeficiency syndrome	0.00145	0.00212	CcSEcCtD
Propylthiouracil—Hepatitis—Lamivudine—acquired immunodeficiency syndrome	0.00145	0.00211	CcSEcCtD
Propylthiouracil—MPO—Vitamin B12 Metabolism—IFNG—acquired immunodeficiency syndrome	0.00144	0.0189	CbGpPWpGaD
Propylthiouracil—Oedema—Zidovudine—acquired immunodeficiency syndrome	0.00144	0.0021	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Zidovudine—acquired immunodeficiency syndrome	0.00141	0.00206	CcSEcCtD
Propylthiouracil—Arthralgia—Indinavir—acquired immunodeficiency syndrome	0.0014	0.00204	CcSEcCtD
Propylthiouracil—Myalgia—Indinavir—acquired immunodeficiency syndrome	0.0014	0.00204	CcSEcCtD
Propylthiouracil—Vertigo—Efavirenz—acquired immunodeficiency syndrome	0.00139	0.00203	CcSEcCtD
Propylthiouracil—DIO1—Metabolism—AGPS—acquired immunodeficiency syndrome	0.00138	0.0181	CbGpPWpGaD
Propylthiouracil—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.00137	0.00199	CcSEcCtD
Propylthiouracil—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.00136	0.00198	CcSEcCtD
Propylthiouracil—DIO1—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	0.00135	0.0177	CbGpPWpGaD
Propylthiouracil—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.00135	0.00197	CcSEcCtD
Propylthiouracil—Dysgeusia—Ritonavir—acquired immunodeficiency syndrome	0.00135	0.00196	CcSEcCtD
Propylthiouracil—Alopecia—Saquinavir—acquired immunodeficiency syndrome	0.00134	0.00196	CcSEcCtD
Propylthiouracil—Oedema—Indinavir—acquired immunodeficiency syndrome	0.00134	0.00196	CcSEcCtD
Propylthiouracil—Vertigo—Delavirdine—acquired immunodeficiency syndrome	0.00133	0.00195	CcSEcCtD
Propylthiouracil—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.00133	0.00194	CcSEcCtD
Propylthiouracil—Leukopenia—Delavirdine—acquired immunodeficiency syndrome	0.00133	0.00194	CcSEcCtD
Propylthiouracil—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.00132	0.00193	CcSEcCtD
Propylthiouracil—Arthralgia—Efavirenz—acquired immunodeficiency syndrome	0.00132	0.00193	CcSEcCtD
Propylthiouracil—Myalgia—Efavirenz—acquired immunodeficiency syndrome	0.00132	0.00193	CcSEcCtD
Propylthiouracil—Rash—Amprenavir—acquired immunodeficiency syndrome	0.00132	0.00193	CcSEcCtD
Propylthiouracil—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.00132	0.00193	CcSEcCtD
Propylthiouracil—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.00132	0.00192	CcSEcCtD
Propylthiouracil—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.00132	0.00192	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	0.00131	0.00192	CcSEcCtD
Propylthiouracil—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00131	0.00191	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Indinavir—acquired immunodeficiency syndrome	0.00131	0.00191	CcSEcCtD
Propylthiouracil—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.00131	0.00191	CcSEcCtD
Propylthiouracil—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.0013	0.00189	CcSEcCtD
Propylthiouracil—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.00129	0.00189	CcSEcCtD
Propylthiouracil—Dysgeusia—Saquinavir—acquired immunodeficiency syndrome	0.00129	0.00189	CcSEcCtD
Propylthiouracil—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.00129	0.00188	CcSEcCtD
Propylthiouracil—MPO—Folate Metabolism—ALB—acquired immunodeficiency syndrome	0.00129	0.0168	CbGpPWpGaD
Propylthiouracil—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.00128	0.00187	CcSEcCtD
Propylthiouracil—Alopecia—Lamivudine—acquired immunodeficiency syndrome	0.00128	0.00187	CcSEcCtD
Propylthiouracil—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.00127	0.00185	CcSEcCtD
Propylthiouracil—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.00126	0.00184	CcSEcCtD
Propylthiouracil—Myalgia—Delavirdine—acquired immunodeficiency syndrome	0.00126	0.00184	CcSEcCtD
Propylthiouracil—TPO—Differentiation Pathway—IL6—acquired immunodeficiency syndrome	0.00126	0.0165	CbGpPWpGaD
Propylthiouracil—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00125	0.00182	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.00124	0.00181	CcSEcCtD
Propylthiouracil—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	0.00124	0.0018	CcSEcCtD
Propylthiouracil—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.00123	0.0018	CcSEcCtD
Propylthiouracil—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	0.00123	0.00179	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.00122	0.00178	CcSEcCtD
Propylthiouracil—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.00122	0.00177	CcSEcCtD
Propylthiouracil—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.00122	0.00177	CcSEcCtD
Propylthiouracil—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.00121	0.00177	CcSEcCtD
Propylthiouracil—MPO—IL23-mediated signaling events—TNF—acquired immunodeficiency syndrome	0.00121	0.0158	CbGpPWpGaD
Propylthiouracil—Rash—Didanosine—acquired immunodeficiency syndrome	0.00121	0.00176	CcSEcCtD
Propylthiouracil—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.0012	0.00176	CcSEcCtD
Propylthiouracil—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.0012	0.00175	CcSEcCtD
Propylthiouracil—Headache—Didanosine—acquired immunodeficiency syndrome	0.0012	0.00175	CcSEcCtD
Propylthiouracil—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.00119	0.00174	CcSEcCtD
Propylthiouracil—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.00119	0.00173	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.00119	0.00173	CcSEcCtD
Propylthiouracil—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.00118	0.00173	CcSEcCtD
Propylthiouracil—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.00118	0.00172	CcSEcCtD
Propylthiouracil—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.00118	0.00172	CcSEcCtD
Propylthiouracil—MPO—Folate Metabolism—IFNG—acquired immunodeficiency syndrome	0.00117	0.0153	CbGpPWpGaD
Propylthiouracil—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00117	0.00171	CcSEcCtD
Propylthiouracil—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.00117	0.0017	CcSEcCtD
Propylthiouracil—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.00117	0.0017	CcSEcCtD
Propylthiouracil—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.00116	0.00169	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.00115	0.00168	CcSEcCtD
Propylthiouracil—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.00115	0.00167	CcSEcCtD
Propylthiouracil—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.00114	0.00166	CcSEcCtD
Propylthiouracil—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.00114	0.00166	CcSEcCtD
Propylthiouracil—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00114	0.00165	CcSEcCtD
Propylthiouracil—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.00113	0.00165	CcSEcCtD
Propylthiouracil—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.00113	0.00165	CcSEcCtD
Propylthiouracil—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.00113	0.00164	CcSEcCtD
Propylthiouracil—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.00113	0.00164	CcSEcCtD
Propylthiouracil—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.00113	0.00164	CcSEcCtD
Propylthiouracil—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.00112	0.00163	CcSEcCtD
Propylthiouracil—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.00112	0.00163	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.0011	0.00161	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.0011	0.0016	CcSEcCtD
Propylthiouracil—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.00109	0.00159	CcSEcCtD
Propylthiouracil—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.00109	0.00159	CcSEcCtD
Propylthiouracil—Rash—Nevirapine—acquired immunodeficiency syndrome	0.00108	0.00158	CcSEcCtD
Propylthiouracil—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.00108	0.00158	CcSEcCtD
Propylthiouracil—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.00108	0.00157	CcSEcCtD
Propylthiouracil—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.00108	0.00157	CcSEcCtD
Propylthiouracil—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00108	0.00157	CcSEcCtD
Propylthiouracil—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.00107	0.00157	CcSEcCtD
Propylthiouracil—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.00107	0.00157	CcSEcCtD
Propylthiouracil—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.00107	0.00156	CcSEcCtD
Propylthiouracil—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.00107	0.00155	CcSEcCtD
Propylthiouracil—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.00106	0.00155	CcSEcCtD
Propylthiouracil—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.00106	0.00154	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.00106	0.00154	CcSEcCtD
Propylthiouracil—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.00105	0.00154	CcSEcCtD
Propylthiouracil—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.00105	0.00153	CcSEcCtD
Propylthiouracil—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.00105	0.00153	CcSEcCtD
Propylthiouracil—Rash—Stavudine—acquired immunodeficiency syndrome	0.00105	0.00153	CcSEcCtD
Propylthiouracil—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.00105	0.00152	CcSEcCtD
Propylthiouracil—MPO—Folate Metabolism—IL2—acquired immunodeficiency syndrome	0.00104	0.0136	CbGpPWpGaD
Propylthiouracil—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.00104	0.00152	CcSEcCtD
Propylthiouracil—Headache—Stavudine—acquired immunodeficiency syndrome	0.00104	0.00152	CcSEcCtD
Propylthiouracil—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.00104	0.00151	CcSEcCtD
Propylthiouracil—Rash—Abacavir—acquired immunodeficiency syndrome	0.00103	0.0015	CcSEcCtD
Propylthiouracil—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.00103	0.0015	CcSEcCtD
Propylthiouracil—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.00103	0.0015	CcSEcCtD
Propylthiouracil—Headache—Abacavir—acquired immunodeficiency syndrome	0.00102	0.00149	CcSEcCtD
Propylthiouracil—MPO—Selenium Micronutrient Network—ALB—acquired immunodeficiency syndrome	0.00102	0.0134	CbGpPWpGaD
Propylthiouracil—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.00102	0.00149	CcSEcCtD
Propylthiouracil—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00102	0.00149	CcSEcCtD
Propylthiouracil—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.00102	0.00149	CcSEcCtD
Propylthiouracil—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.00101	0.00147	CcSEcCtD
Propylthiouracil—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.00101	0.00147	CcSEcCtD
Propylthiouracil—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.00101	0.00147	CcSEcCtD
Propylthiouracil—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.001	0.00146	CcSEcCtD
Propylthiouracil—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000997	0.00145	CcSEcCtD
Propylthiouracil—DBH—Metabolism—TAT—acquired immunodeficiency syndrome	0.000995	0.013	CbGpPWpGaD
Propylthiouracil—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000989	0.00144	CcSEcCtD
Propylthiouracil—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000987	0.00144	CcSEcCtD
Propylthiouracil—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000986	0.00144	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000983	0.00143	CcSEcCtD
Propylthiouracil—MPO—IL23-mediated signaling events—IL6—acquired immunodeficiency syndrome	0.000974	0.0127	CbGpPWpGaD
Propylthiouracil—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000971	0.00142	CcSEcCtD
Propylthiouracil—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000969	0.00141	CcSEcCtD
Propylthiouracil—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000963	0.0014	CcSEcCtD
Propylthiouracil—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000959	0.0014	CcSEcCtD
Propylthiouracil—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000958	0.0014	CcSEcCtD
Propylthiouracil—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.00095	0.00138	CcSEcCtD
Propylthiouracil—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000949	0.00138	CcSEcCtD
Propylthiouracil—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000938	0.00137	CcSEcCtD
Propylthiouracil—TPO—Metabolism—TAT—acquired immunodeficiency syndrome	0.000935	0.0122	CbGpPWpGaD
Propylthiouracil—MPO—C-MYB transcription factor network—CD4—acquired immunodeficiency syndrome	0.000935	0.0122	CbGpPWpGaD
Propylthiouracil—MPO—Vitamin B12 Metabolism—TNF—acquired immunodeficiency syndrome	0.000934	0.0122	CbGpPWpGaD
Propylthiouracil—MPO—Selenium Micronutrient Network—IFNG—acquired immunodeficiency syndrome	0.000933	0.0122	CbGpPWpGaD
Propylthiouracil—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000924	0.00135	CcSEcCtD
Propylthiouracil—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000917	0.00134	CcSEcCtD
Propylthiouracil—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000915	0.00133	CcSEcCtD
Propylthiouracil—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000909	0.00133	CcSEcCtD
Propylthiouracil—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000908	0.00132	CcSEcCtD
Propylthiouracil—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000906	0.00132	CcSEcCtD
Propylthiouracil—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000903	0.00132	CcSEcCtD
Propylthiouracil—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000897	0.00131	CcSEcCtD
Propylthiouracil—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000891	0.0013	CcSEcCtD
Propylthiouracil—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000886	0.00129	CcSEcCtD
Propylthiouracil—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000858	0.00125	CcSEcCtD
Propylthiouracil—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000857	0.00125	CcSEcCtD
Propylthiouracil—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000857	0.00125	CcSEcCtD
Propylthiouracil—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000853	0.00124	CcSEcCtD
Propylthiouracil—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000853	0.00124	CcSEcCtD
Propylthiouracil—DBH—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000846	0.0111	CbGpPWpGaD
Propylthiouracil—Rash—Indinavir—acquired immunodeficiency syndrome	0.000846	0.00123	CcSEcCtD
Propylthiouracil—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000845	0.00123	CcSEcCtD
Propylthiouracil—Headache—Indinavir—acquired immunodeficiency syndrome	0.00084	0.00122	CcSEcCtD
Propylthiouracil—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000818	0.00119	CcSEcCtD
Propylthiouracil—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000814	0.00119	CcSEcCtD
Propylthiouracil—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000806	0.00117	CcSEcCtD
Propylthiouracil—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000799	0.00116	CcSEcCtD
Propylthiouracil—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000798	0.00116	CcSEcCtD
Propylthiouracil—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000797	0.00116	CcSEcCtD
Propylthiouracil—TPO—Metabolism—AGPS—acquired immunodeficiency syndrome	0.000795	0.0104	CbGpPWpGaD
Propylthiouracil—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000794	0.00116	CcSEcCtD
Propylthiouracil—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000793	0.00116	CcSEcCtD
Propylthiouracil—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000771	0.00112	CcSEcCtD
Propylthiouracil—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000764	0.00111	CcSEcCtD
Propylthiouracil—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000764	0.00111	CcSEcCtD
Propylthiouracil—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000763	0.00111	CcSEcCtD
Propylthiouracil—MPO—Folate Metabolism—TNF—acquired immunodeficiency syndrome	0.00076	0.00993	CbGpPWpGaD
Propylthiouracil—Headache—Delavirdine—acquired immunodeficiency syndrome	0.00076	0.00111	CcSEcCtD
Propylthiouracil—MPO—Vitamin B12 Metabolism—IL6—acquired immunodeficiency syndrome	0.000754	0.00985	CbGpPWpGaD
Propylthiouracil—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000753	0.0011	CcSEcCtD
Propylthiouracil—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000728	0.00106	CcSEcCtD
Propylthiouracil—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00072	0.00105	CcSEcCtD
Propylthiouracil—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000713	0.00104	CcSEcCtD
Propylthiouracil—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000707	0.00103	CcSEcCtD
Propylthiouracil—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000706	0.00103	CcSEcCtD
Propylthiouracil—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000702	0.00102	CcSEcCtD
Propylthiouracil—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000686	0.001	CcSEcCtD
Propylthiouracil—Rash—Saquinavir—acquired immunodeficiency syndrome	0.00068	0.000992	CcSEcCtD
Propylthiouracil—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.00068	0.000991	CcSEcCtD
Propylthiouracil—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000676	0.000985	CcSEcCtD
Propylthiouracil—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000666	0.000971	CcSEcCtD
Propylthiouracil—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000655	0.000954	CcSEcCtD
Propylthiouracil—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000649	0.000946	CcSEcCtD
Propylthiouracil—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000649	0.000945	CcSEcCtD
Propylthiouracil—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000645	0.00094	CcSEcCtD
Propylthiouracil—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000641	0.000934	CcSEcCtD
Propylthiouracil—MPO—Folate Metabolism—IL6—acquired immunodeficiency syndrome	0.000613	0.00801	CbGpPWpGaD
Propylthiouracil—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000612	0.000891	CcSEcCtD
Propylthiouracil—MPO—Selenium Micronutrient Network—TNF—acquired immunodeficiency syndrome	0.000604	0.00789	CbGpPWpGaD
Propylthiouracil—MPO—Selenium Micronutrient Network—IL6—acquired immunodeficiency syndrome	0.000487	0.00637	CbGpPWpGaD
Propylthiouracil—DIO1—Metabolism—ALB—acquired immunodeficiency syndrome	0.000284	0.00371	CbGpPWpGaD
Propylthiouracil—DBH—Metabolism—ALB—acquired immunodeficiency syndrome	0.000173	0.00227	CbGpPWpGaD
Propylthiouracil—TPO—Metabolism—ALB—acquired immunodeficiency syndrome	0.000163	0.00213	CbGpPWpGaD
